Tarsus Pharmaceuticals, Inc. (TARS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US87650L1035
Tarsus Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 451.36 m USD |
| Operating income | -70.97 m USD |
| EBIT | -55.42 m USD |
| Net income | -66.42 m USD |
| Diluted EPS – continuing operations | -1.59 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
More stocks
- Zhefu Holding Group Co Ltd (002266.SZ)
- China Railway Construction Heavy Industry Corp Ltd (688425.SS)
- Shanghai Daimay Auto Interior (603730.SS)
- Organización Soriana S. A. B. de C. V (SORIANAB.MX)
- GOLUB CAPITAL BDC, Inc. (GBDC)
- Shenzhen O-Film Tech Co Ltd (002456.SZ)
- Novoray Corporation (688300.SS)
- Atlanta Braves Holdings, Inc. (BATRK)
- AVISTA CORP (AVA)
- Iguatemi S.A. (IGTI4.SA)
- ABM INDUSTRIES INC /DE/ (ABM)
- Feilong Auto Components Co Ltd (002536.SZ)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.